Cargando…
Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
Oncogenic BRAF mutations have been widely described in melanomas and promote tumour progression and chemoresistance. We previously provided evidence that the HDAC inhibitor ITF2357 (Givinostat) targets oncogenic BRAF in SK-MEL-28 and A375 melanoma cells. Here, we show that oncogenic BRAF localises t...
Autores principales: | Celesia, Adriana, Franzò, Marzia, Di Liberto, Diana, Lauricella, Marianna, Carlisi, Daniela, D’Anneo, Antonella, Notaro, Antonietta, Allegra, Mario, Giuliano, Michela, Emanuele, Sonia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252263/ https://www.ncbi.nlm.nih.gov/pubmed/37298104 http://dx.doi.org/10.3390/ijms24119148 |
Ejemplares similares
-
The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis
por: Celesia, Adriana, et al.
Publicado: (2022) -
Analysis of Givinostat/ITF2357 Treatment in a Rat Model of Neonatal Hypoxic-Ischemic Brain Damage
por: Pawelec, Paulina, et al.
Publicado: (2022) -
Inhibition of the Autophagy Pathway Synergistically Potentiates the Cytotoxic Activity of Givinostat (ITF2357) on Human Glioblastoma Cancer Stem Cells
por: Angeletti, Francesca, et al.
Publicado: (2016) -
Parthenolide and Its Soluble Analogues: Multitasking Compounds with Antitumor Properties
por: Carlisi, Daniela, et al.
Publicado: (2022) -
Long non-coding RNA H19 enhances the pro-apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells
por: Zichittella, Chiara, et al.
Publicado: (2023)